Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Headache and Migraine
NeurAxon Announces Positive Phase 1 Trial Data on NXN-188 for Migraine
August 27th, 2007
NeurAxon, Inc., a developer of next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), announced positive data from its Phase 1 clinical trial for NXN-188 assessing the safety and establishing the pharmacokinetic profile of the investigational drug candidate. NXN-188 is a first-in-class, dual-action, small molecule that is being developed for the treatment of acute migraine and which incorporates both 5-HT agonism (the mechanism of action of triptans, the current standard of care in migraine therapy) and nNOS inhibition. NOS is a validated target for migraine therapy as migraine models indicate that nNOS inhibition can relieve pain. Additionally, nitric oxide...
Source: Clinical Trials Week (2007-08-27)
|
